INTRODUCTION

Acute coronary syndrome (ACS) is characterized by acute onset, poor prognosis and high mortality rate, which seriously jeopardizes the life and health of patients. The erosion or rupture of unstable plaques in the coronary artery leads to thrombosis and decrease or even interruption of myocardial blood flow, thus endangering life. Percutaneous coronary intervention (PCI) is a commonly used clinical method to control the deterioration of ACS, but not all ACS patients can benefit from it. Oxidative stress and inflammation have been
proven to play vital roles in the occurrence and development of ACS. Inflammatory reaction markers, such as C-reactive protein, neutrophil-to-lymphocyte ratio and platelet-to-lymphocytes ratio, have become independent predictors for coronary artery disease and are closely associated with the prognosis of ACS. The monocyte to high-density lipoprotein ratio (MHR), as a new indicator for inflammation, is of great significance in coronary artery-related diseases. The role of MHR in ACS after PCI has never been reported. This study aimed to explore the correlation between MHR and major adverse cardiovascular events (MACE) after PCI, and to provide new predictors for high-risk ACS patients in clinical practice.

**METHODS**

In this retrospective study, 120 ACS patients who received PCI in our hospital from September 2014 to August 2019 were selected, and their clinical data were collected. There were 68 males and 52 females aged 43-92 years old, with an average age of (62.04 ± 10.87) years old. All patients were divided into MACE group (n=39), including 10 cases of sudden cardiac arrest, eight cases of cardiogenic shock, 16 cases of malignant arrhythmia and five deaths, and normal discharge (ND) group (n=81). This study was approved by the Ethics Committee of the hospital (approval No. 2014037; date: August 27th, 2014), and all patients signed the informed consent.

**Inclusion criteria:** The patients were diagnosed according to the diagnostic criteria of ACS in Internal Medicine (8th edition) published by People’s Medical Publishing House Co., Ltd.:
1. Dynamically changing electrocardiograms.
2. Appearance of myocardial ischemia.
3. Lumen stenosis ≥50% in at least one main vessel (such as right coronary artery, left main artery, left circumflex branch and left anterior descending branch) shown in coronary angiography.
4. Weakened function of the ventricular wall shown in cardiac ultrasound.
5. Increased troponins.
6. Abnormal periodic movement.

**Exclusion criteria:**
1. Patients with myocarditis.
2. Those who received thrombolytic therapy for coronary heart disease.
3. Those with past history of cardiac surgery.
4. Those with autoimmune diseases.
5. Those with active infection and chronic inflammatory diseases.
6. Those with liver and kidney failure or those complicated with serious medical diseases.
7. Those suffering from malignant tumors.
8. Those who were not suitable for PCI.
9. Those with incomplete clinical data.

**Criteria for performing PCI:** According to the related standards of 2010 American Heart Association Guidelines for PCI, ACS patients with PCI indications were treated with PCI.

**Gensini scoring criteria for coronary artery disease:** Clinically, coronary angiography is applied to quantitatively evaluate the stenosis degree of coronary artery disease. The product of the stenosis score of each coronary artery and the coronary segment score is the Gensini score of the coronary artery disease. The scoring criteria of coronary angiography results are shown in Table-I.

**Definition of MACE:** MACE occurred during hospitalization after PCI, including cardiac death, ventricular fibrillation, congestive heart failure, malignant arrhythmia, cardiovascular atherosclerosis, cardiac arrest, hypoxic encephalopathy and ischemic stroke.

**Collection of baseline clinical data:** The baseline clinical data of patients were collected, including diabetes, hypertension, smoking history and other clinical parameters. After admission and fasting for 10 hour, 5 mL of venous blood was drawn in the early morning on the next day. The whole blood anticoagulated with dipotassium ethylenediaminetetraacetic acid (EDTA-K2) was detected using a BC-5300 full-automatic hematology analyzer, and

### Table-I: Gensini scoring criteria of coronary angiography results.

| Stenosis degree | Score (point) |
|-----------------|---------------|
| 1%-25%          | 1             |
| 26%-50%         | 2             |
| 51%-75%         | 4             |
| 76%-90%         | 8             |
| 91%-99%         | 16            |
| 100%            | 32            |

| Lesion site     | Score (point) |
|-----------------|---------------|
| Left main artery| 5             |
| Proximal segment of left anterior descending branch or circumflex artery | 2.5 |
| Middle segment of left anterior descending branch | 1.5 |
| Distal segment of left anterior descending branch | 1 |
| Middle and distal segments of left circumflex branch | 1 |
| Proximal, middle and distal segments of right coronary artery | 1 |
| Small branch    | 0.5           |
the white blood cell count and monocyte count (M) were obtained. Then low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), triglyceride (TG), apolipoprotein A1 (ApoA1), ApoB, lipoprotein (a) [LP(a)] and uric acid (UA) were examined using an AU5800 fully automatic chemistry analyzer (Beckman Coulter). The ratio of M to HDL was MHR.

**Coronary angiography:** The Allen test results of the included patients were negative. Following local anesthesia, the contrast agent was injected through radial artery puncture, and Siemens Artis Zeego III digital angiography machine was utilized to quantitatively assess the coronary artery stenosis. The examination was performed and the results were recorded by two experienced interventional cardiologists in our hospital.

**Statistical analysis:** All data were statistically analyzed by SPSS 20.0 software. The quantitative data conforming to normal distribution were expressed as mean ± standard deviation, and intergroup comparisons were carried out by the independent samples t test. The numerical data were represented as percentage (%), and intergroup comparisons were performed with the χ² test. Logistic regression analysis was conducted to analyze the correlations between various factors and ACS. The correlation between MHR and Gensini score was subjected to Pearson’s analysis. ROC curve analysis of diagnostic value of MHR for MACE: The ROC curve of MHR was assessed, and the area under the curve was 0.827, indicating that MHR has high diagnostic value for MACE. Besides, the optimal cutoff value for diagnosing based on MHR was 9.45 (Fig.2).

**RESULTS**

**Baseline clinical data:** The baseline data of the two groups of patients were analyzed, and it was found that hypertension degree, white blood cell count, Gensini score, MHR and the levels of TC, TG, LDLC, HDLC, ApoA1, ApoB, LP(a) and UA in MACE group were significantly higher than those in ND group, and the differences were statistically significant (P<0.05). The remaining data such as gender, age, smoking history, diabetes, coronary heart disease, body mass index and M in the two groups were not significantly different, without statistical significance (P>0.05) (Table-II).

| MACE | ND | P  |
|------|----|----|
| group | (n=39) | (n=81) |
| Male [case, (%)] | 26 (66.67) | 42 (51.85) | 0.125 |
| Age (year) | 68.65±5.56 | 62.58±7.12 | 0.021 |
| Smoking [case, (%)] | 18 (46.15) | 41 (50.61) | 0.740 |
| Hypertension [case, (%)] | 27 (71.01) | 39 (48.14) | 0.030* |
| Diabetes mellitus [case, (%)] | 22 (56.41) | 43 (53.09) | 0.730 |
| Coronary artery disease [case, (%)] | 20 (51.28) | 37 (45.68) | 0.560 |
| BMI (kg/m²) | 23.41±5.35 | 25.36±2.23 | 0.686 |
| WBC count (×10⁶/L) | 12.35±4.31 | 9.25±2.68 | 0.001* |
| M (×10⁶/L) | 0.57±0.25 | 0.48±0.13 | 0.680 |
| TC (mmol/L) | 4.55±0.88 | 2.35±0.37 | 0.001* |
| TG (mmol/L) | 2.69±0.29 | 1.60±0.35 | <0.001* |
| LDLC (mmol/L) | 2.34±0.25 | 2.49±0.12 | <0.001* |
| HDLC (mmol/L) | 2.25±0.33 | 1.14±0.36 | <0.001* |
| ApoA1 (mmol/L) | 17.18±0.37 | 6.85±0.53 | <0.001* |
| ApoB (mmol/L) | 1.13±0.25 | 0.75±0.06 | <0.001* |
| LP(a) (mmol/L) | 310.36±150.52 | 113.96±93.25 | <0.001* |
| UA (mmol/L) | 4.56±0.88 | 1.25±0.29 | <0.001* |
| Gensini score | 45.87±3.85 | 32.57±2.71 | 0.03* |
| MHR | 16.59±2.61 | 8.41±2.64 | <0.001* |

**Table-II:** Baseline clinical data.

| Index | β | SE  | Wald | P  | OR  | 95%CI |
|-------|---|-----|------|----|-----|------|
| M     | -4.03 | 2.98 | 2.62 | 0.15 | 0.08 | 0.01~2.72 |
| ApoA1 | -1.21 | 0.75 | 1.93 | 0.02 | 1.34 | 1.01~2.97 |
| ApoB  | 2.34 | 1.08 | 4.26 | 0.01 | 1.12 | 1.07~1.39 |
| HDLC  | -1.87 | 0.93 | 3.89 | 0.02 | 1.49 | 1.25~3.85 |
| LDLC  | 1.32 | 0.32 | 18.94 | 0.00 | 4.36 | 2.53~8.67 |
| TC    | -0.03 | 0.02 | 0.01 | 0.91 | 9.01 | 5.98~14.62 |
| TG    | 0.95 | 0.38 | 8.06 | 0.18 | 2.84 | 0.87~8.91 |

**Table-III:** Logistic regression analysis results.

**DISCUSSION**

Inflammation is the key factor in the course of coronary artery disease, and persistent inflammation is the main pathological process of ACS. The abnormal expression of inflammatory factors is related to the formation, development and rupture of plaque in the course of coronary atherosclerosis.
Currently, numerous inflammatory mediators or markers have become predictors for the development of coronary artery disease. In recent years, the association between MHR and the progression of ACS has attracted wide concern and is expected to become a new predictor for the course of ACS.

Abnormal blood lipid in the body exerts a very crucial effect in the deterioration of cardiovascular diseases. At present, primary hospitals in China can detect four blood lipid indices, i.e. TC, TG, LDLC and HDLC. It has been shown in a study that the change of blood viscosity triggered by lipid metabolism disorder greatly increases the risk of MACE and even death. Herein, the levels of TC, TG, LDLC and HDLC in patients in MACE group were significantly higher than those in ND group. The lipid metabolism disorder in ACS patients is triggered by the joint action of multiple effector cells and cytokines. In addition, macrophages transformed from monocytes in serum are the initiating cells of plaque formation in ACS. Macrophages phagocytize LDL and its apolipoprotein ApoB lipid particles and deposits on the vascular endothelium. After gathering to a certain extent, macrophages transform into foam cells, and then rupture and die, thereby contributing to the malignant development of ACS. In the meantime, monocytes recruited by inflammatory stress can also facilitate the transformation of oxidized LDL and other intimal lipids into foam cells in the process of ACS plaque formation, which are continuously deposited on the intimal of blood vessels, eventually leading to coronary artery stenosis and MACE. Karabacak et al. reported that HDLC and its apolipoprotein ApoA1 promoted the efflux of TC, inhibited the activation of antigen CD11b on the activation of monocyte surface, and performed functions of anti-inflammation, anti-oxidation, anti-atherosclerosis and anti-plaque formation in the development of ACS. Therefore, MHR can be used as an inflammatory indicator to manifest coronary artery lesions, and it can reflect the lesion degree of coronary artery plaques in ACS patients from “formation mechanism” and “protection mechanism”.

Akboga et al. indicated that MHR was an independent predictor for unstable atherosclerotic plaques in patients with coronary heart disease. Cetin et al. found that MHR exhibited a positive association with ACS and showed an obvious relationship with MACEs and the clinical endpoint of ACS patients. Besides, Canpolat et al. confirmed that MHR was an independent predictor for the early relapse of paroxysmal atrial fibrillation after radiofrequency ablation. Moreover, Kundi et al. pointed out that MHR was superior to single M or HDLC concentration in predicting the occurrence and development of coronary artery lesions and cardiovascular events. In this study, the results displayed that hypertension degree, white blood cell count, Gensini score and MHR in MACE group were significantly higher than those in ND group (P<0.05). It was discovered from the logistic regression analysis that HDLC, ApoA1, TC, MHR, LDLC and ApoB were independent risk factors for MACE of ACS patients after PCI. Additionally, Pearson’s correlation analysis revealed that MHR was positively correlated with Gensini score (r=0.832, P<0.05). Lastly, ROC curve analysis proved that MHR had high diagnostic value for MACE.
**Limitations of the study:** This is a single-center study with a low number of included cases. Further multicenter prospective studies are ongoing in our group to verify the predictive value of MHR for MACE of ACS patients after PCI.

**CONCLUSION**

MHR is positively correlated with Gensini score in ACS patients after PCI, and it can be used as an independent predictor for MACE in hospital. Clinicians should comprehensively analyze the clinical risks of MHR in light of the specific conditions of each patient, so as to make a more scientific and effective treatment regimen.

**Conflict of interest:** None.

**Source of funding:** None.

**REFERENCES**

1. Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, Alvarez-Sangabriel A, Eid-Lidt G, Gonzalez-Hermosillo A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol. 2015;66:2:148-154. doi: 10.1016/j.jjc.2014.11.001

2. Schwartz GG, Steg PG, Szaranek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. doi: 10.1056/NEJMoa1801174

3. Lopes RD, Heizler G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi: 10.1056/NEJMoa1817083

4. Korkmaz A, Demir M, Unal S, Yildiz A, Ozyazgan B, Demirtas B, et al. Monocyte-to-high density lipoprotein ratio (MHR) can predict the significance of angiographically intermediate coronary lesions. Int J Cardiovasc Acad. 2017;3(1-2):16-20. doi: 10.1016/j.jjcc.2017.05.008

5. Ray KK, Colhoun HM, Szarez M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the odyssey outcomes randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5

6. Garg P, Morris P, Fazlamine AL, Vijayan S, Dancso B, Dastidar AG, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017;12(2):147-155. doi: 10.1007/s11739-017-1612-1

7. Shah PK. Inflammation, infection and atherosclerosis. Trend Cardiovasc Med. 2019;29(8):468-472. doi: 10.1016/j.tcm.2019.01.004

8. Yang J, Fang X, Zhang J, Qing MI, Mou H. Effects of Rosuvastatin Combined with Tirofiban on Serum Inflammatory Factors and Renal Function in Acute Coronary Syndrome Patients with Diabetes after PCI. China Pharm. 2018;29(5):679-683.

9. Sun XQ, Li YF, Meng YJ, Shi GF. Effect of rosuvastatin intensification therapy on blood lipid metabolism, adipocytokines and plaque stability after PCI in ACS patients. J Hainan Med Univ. 2017;25(1):59-62.

10. Shi XJ, Li MN, Xuan L, Li H, Chen B, Zhang J, et al. Clinical characteristics of patients with premature acute coronary syndrome and adverse cardiovascular events after PCI. Exp Ther Med. 2019;18(1):793-801. doi: 10.3892/etm.2019.7618

11. Tang J, Lobatto ME, Hassing L, Van Der Staay S, Van Rijs SM, Calcagno C, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv. 2015;1(3):e1400223. doi: 10.1126/sciadv.1400223

12. Rangel-Huerta OD, Pastor-Villaescusa B, Agullera CM, Gil A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: phenolic compounds. Nutrients. 2015;7(7):5177-5216. doi: 10.3390/nu7075177

13. Xianzhao F, Zhenfeng H, Wenhua H, Wanli T, Chunyan L, Xingshou P, et al. Review and Prospect of the Preventive Effect of “Supplementing Qi and Nourishing Yin, Activating Blood Circulation and Detoxifying” on Diabetes Mellitus Complicated with Acute Coronary Syndrome. Am J Clin Exp Med. 2018;6(4):87-93.

14. Karabacak M, Kahraman F, Sert M, Celik E, Adali MK, Varol E. Increased plasma monocyte chemoattractant protein-1 levels in patients with isolated low-density lipoprotein cholesterol. Scand J Clin Lab Invest. 2015;75(4):327-332. doi: 10.3109/00365513.2014.1003595

15. Akboga MK, Balci KG, Maden O, Ertem AG, Kirbas O, Yavla C, et al. Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark Med. 2016;10(4):375-383. doi: 10.2217/ bm-2015-0090

16. Cetin MS, Cetin EH, Kalender E, Aydin S, Topaloglu S, Kisasli HL, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ. 2016;25(11):1077-1086. doi: 10.1016/j.hlc.2016.02.023

17. Canpolat U, Aytemir K, Yorgun H, Sahiner L, Kaya EB, Cay S, et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace. 2015;17(12):1807-1815. doi: 10.1093/europace/euu291

18. Kundi H, Kizilunc E, Cetin M, Cieckiglou H, Cetin ZG, Cieck G, et al. Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz. 2016;41(6):523-529. doi: 10.1007/s00059-015-4393-1

**Authors’ contributions:**

**RY & JA:** Study design and significant manuscript revision.

**RH, TW, TL & HH:** manuscript drafting, clinical data collection and analysis.

**RY, RH, TW, TL, HH & JA:** approval of manuscript submission.

All authors are responsible and accountable for the accuracy or integrity of the work.

**Authors:**

1. Rong Yu, Department of Medicine, The Second Hospital of Shaxi Medical University, Taiyuan 030001, China.
2. Ruigang Hou, Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan 030001, China.
3. Tong Wang, Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan 030001, China.
4. Tianliang Li, Department of Cardiology, Taiyuan 030001, China.